Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;19(3):200-202.
doi: 10.3909/riu193PracticeProfile.

Imaging and treatment recommendations in patients with castrate-resistant prostate cancer

David M Albala  1
Affiliations

Imaging and treatment recommendations in patients with castrate-resistant prostate cancer

David M Albala. Rev Urol. 2017.
No abstract available

PubMed Disclaimer

References

    1. Crawford ED, Petrylak D, Shore N, et al. S. The role of therapeutic layering in optimizing treatment for patients with castration-resistant prostate cancer. Urology. 2017;104:150159. - PubMed
    1. Armstrong AJ, Saad F, Phung D, et al. Clinical outcomes and survival surrogacy studies of prostatespecific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017;123:2303–2311. - PMC - PubMed
    1. El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2013;5:25–40. - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. (2010) Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. - PubMed
    1. Lorente D, Mateo J, Perez-Lopez R, et al. (2015) Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e279–e292. - PubMed

LinkOut - more resources